Malattia Leventinese, or Doyne Honeycomb Retinal Dystrophy, is a rare genetic eye disorder that has long intrigued researchers due to its striking clinical presentation and specific genetic etiology. The condition is caused by a single missense mutation (Arg345Trp or R345W) in the EFEMP1 gene, which encodes the epidermal growth factor-containing fibulin-like extracellular matrix protein 1.
Recent comprehensive reviews and natural history studies have shed further light on the exact mechanisms by which this mutation leads to disease. The R345W mutation causes the EFEMP1 protein to misfold and accumulate aberrantly within the retinal pigment epithelium (RPE) and the underlying Bruch's membrane. This accumulation is a primary driver of drusen formation—the hallmark of Malattia Leventinese.
Understanding this pathway is critical because it draws parallels with age-related macular degeneration (AMD), a much more common cause of vision loss that also features drusen. However, unlike AMD, which is multifactorial, Malattia Leventinese provides a monogenic model for studying drusen biogenesis.
Researchers are now focusing on how to clear this aberrant protein accumulation or prevent its misfolding in the first place. These insights not only pave the way for targeted gene therapies for Malattia Leventinese but also hold potential implications for the broader understanding and treatment of AMD.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.